23G微创玻璃体切割术治疗玻璃体积血临床疗效观察
Clinical Efficacy of 23-Gauge Transconjunctival Sutureless Vitrectomy for Vitreous Hemorrhage
-
摘要: [摘要]目的 观察23G经结膜无缝合玻璃体切割系统(23G TSV)在玻璃体积血中应用的疗效及安全性.方法 回顾性分析曲靖市第二人民医院2013年5月至2015年6月通过23G玻璃体切割术治疗的保守治疗无效的玻璃体积血患者共38例(43眼),术后随访2~14个月.观察最佳矫正视力,眼压,术中及术后并发症等.结果 38例(43眼)玻璃体积血患者术后视力均有明显提高,和治疗前相比存在差异(P<0.05);术后患者伴有不同并发症,以白内障6眼,高眼压1眼,低眼压3眼等,经基础性处理后均恢复正常.结论 临床对玻璃体积血患者行23G微创玻璃体切割术是一种安全有效的治疗手段,可不同程度的提高视力,避免视功能丧失,值得临床推广.
-
关键词:
- [关键词]23G玻璃体切割术 /
- 玻璃体积血 /
- 临床观察
Abstract: [Abstract]Objective To investigate the clinical efficacy of 23-gauge transconjunctival sutureless vitrectomy (23G TSV) system in the treatment of vitreous hemorrhage. Methods 38 patients (43 eyes) underwent 23-gauge vitrectomy in our hospital from May 2013 to June 2015, and their clinical data were retrospectively analyzed. All patients were followed up 2 to 14 months after operation. We observed the best corrected visual acuity (BCVA),intraocular pressure(IOP)and postoperative complications. Results All cases were successfully performed and the postoperative BCVA had been improved. There were significant differences in BCVA between postoperative and preoperative(P < 0.05). Few postoperative complications were observed, including cataract in 6 eyes, high IOP in 1 eye and low IOP in 3 eyes. However, all complications disappeared after a basic treatment. Conclusion 23G TSV system is an effective and safe surgical technique in the management of vitreous hemorrhage, which can improve the patients' visual and avoid the loss of visual function. It is worthy of clinical promotion.
点击查看大图
计量
- 文章访问数: 2735
- HTML全文浏览量: 997
- PDF下载量: 247
- 被引次数: 0